Did lanadelumab reduce the number of attacks for adults with Hereditary Angioedema in China?
Lanadelumab is a medication approved in China for preventing hereditary angioedema (HAE) attacks. A phase 3 study specifically looked at how well it worked for adults in China. The results showed a very large reduction in attack rates over six months of treatment.
What the research says
A phase 3 study in China enrolled 20 adults with HAE type I or II who had at least one attack during a 4-week run-in period 2. They received lanadelumab 300 mg every 2 weeks for 26 weeks (14 doses total) 2. The mean monthly attack rate dropped by 99.1% compared to the run-in period: from 2.50 attacks per month to 0.04 attacks per month 2. Eighteen out of 20 patients (90%) had no attacks at all during the treatment period 2. These results are consistent with earlier global studies, such as a 2018 phase 3 trial that also found lanadelumab significantly reduced attack rates compared to placebo 5. A 2022 Cochrane review confirmed that lanadelumab is effective for long-term prevention of HAE attacks 6. Additionally, a small study in Hong Kong reported similar benefits, with patients experiencing an average reduction of 2.4 attacks per month and over 70% becoming attack-free 7.
What to ask your doctor
- Is lanadelumab a good option for preventing my HAE attacks?
- What are the common side effects of lanadelumab, such as injection site reactions?
- How often would I need to receive lanadelumab injections?
- Are there any other long-term prevention treatments I should consider?
- How will we monitor if the treatment is working for me?
This question is drawn from common patient questions about Allergy & Immunology and answered using cited medical research. We do not provide individualized advice.